Montara Therapeutics Inc. has been awarded a research grant of approximately $1 million from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to advance a Brainonly therapy targeting mTOR for Parkinson’s disease.
Work at Trained Therapeutix Discovery Inc. has led to the development of new mammalian target of rapamycin (mTOR; FRAP1) inhibitors and high-density lipoprotein (HDL)-derived nanoparticles potentially useful for the treatment of autoimmune diseases, transplant rejection, inflammatory and cardiovascular disorders.
Dysregulation of the mechanistic target of rapamycin (mTOR) signaling pathway is frequently observed across a wide range of cancers and contributes to uncontrolled cell proliferation, enhanced cellular metabolism, and tumor progression.
Galderma Holding SA has identified metabolites of CD-14547 acting as mammalian target of rapamycin (mTOR; FRAP1) inhibitors. As such, they are reported to be useful for the treatment of acne, atopic dermatitis, actinic keratosis and psoriasis.
Aliad Biopharma Co. Ltd. has presented compounds acting as autophagy inducer, mTOR complex 1 (mTORC1) and mTORC2 inhibitors reported to be useful for the treatment of autism spectrum disorders, Alzheimer’s disease, epilepsy, fragile-X syndrome, macrocephaly and tuberous sclerosis.
The first approval for treating advanced malignant perivascular epithelioid cell tumor (PEComa) in adults has been awarded by the FDA to Aadi Bioscience Inc.’s Fyarro. The number of patients is low, from 100 to 300 patients annually in the U.S., but the geography the company hopes to sell to is wide as it takes in Europe and China.
